Ribbon antisense (RiAS) to the hTR RNA, a component of the telomerase complex, was employed to inhibit telomerase activity and cancer cell growth. The antisense molecule, hTR-RiAS, combined with enhanced cellular uptake was shown to effectively inhibit telomerase activity and cause rapid cell death in various cancer cell lines. When cancer cells were treated with hTR-RiAS, the level of hTR RNA was reduced by more than 90% accompanied with reduction in telomerase activity. When checked for cancer cell viability, cancer cell lines treated with hTR-RiAS using DNA þ Peptide þ Lipid complex showed 70-80% growth inhibition in 3 days. The reduced cell viability was due to apoptosis as the percentage of cells exhibiting the sub-G 0 arrest and DNA fragmentation increased after antisense treatment. Further, when subcutaneous tumors of a colon cancer cell line (SW480) were treated intratumorally with hTR-RiAS, tumor growth was markedly suppressed with almost total ablation of hTR RNA in the tumor tissue. Cells in the tumor tissue were also found to undergo apoptosis after hTR-RiAS treatment. These results suggest that hTR-RiAS is an effective anticancer reagent, with a potential for broad efficacy to diverse malignant tumors.
Introduction
Telomeres maintain the integrity of chromosomes by protecting chromosomes from end to end fusion, degradation, and rearrangements (Blackburn, 1991) . Telomeres become progressively shortened by 50-200 bp in each cell division due to the inability of DNA polymerase to replicate the end of chromosomes in somatic cells. When the end of a shortened chromosome reaches a critical point, the shortening is believed to induce the senescence of cells.
Telomerase is a ribonucleoprotein DNA polymerase that elongates telomeric repeats of telomere in eucaryotic cells and play an important role in multiple cellular processes including cell differentiation, senescence, proliferation, and possibly DNA repair (Nugent et al., 1998; Fu et al., 1999; Ishikawa et al., 1999; Urquidi et al., 2000) . Immortalized cells show activation of telomerase and thus indefinitely maintain the telomere structure of a chromosome. Telomerase activity is detected in 85-90% of malignant tumors, while it is not detectable in normal human somatic cells (Kim et al., 1994; Kondo et al., 2000) . It indicates that telomerase activation is an important factor in neoplastic transformation. Thus, an effective approach for eliminating a component of the telomerase complex may prove to be efficacious for a broad spectrum of human cancer.
Human telomerase consists of three major subunits: hTR (human telomerase RNA template) (Feng et al., 1995) , hTERT (human telomerase reverse transcriptase) (Meyerson et al., 1997; Nakamura et al., 1997) , and TP1 (telomerase-associated protein1) (Harrington et al., 1997; Nakayama et al., 1997) . The RNA template, hTR contains the sequence of 5 0 -CUAACCCUAAC-3 0 through which telomerase can extend telomeric repeats. Among the three major components of human telomerase, antisense-based strategies have been attempted against hTR and hTERT both in vitro and in vivo studies to inhibit telomerase activity. These inhibitors to hTR RNA have adopted antisense chemistries of 2-5A antisense, peptide nucleic acid, and ribozymes (Norton et al., 1996; Glukhov et al., 1998; Herbert et al., 1999; Mukai et al., 2000) . Gastric carcinoma cells treated with antisense hTR lose telomeric repeats, resulting in cell death or cellular senescence (Naka et al., 1999) . Tumor cells transfected with antisense inhibiting telomerase activity undergo either apoptosis or differentiation (Kondo et al., 1998) .
We have developed a series of antisense molecules with enhanced stability and low toxicity (Moon et al., 2000a, b) . Among these, ribbon antisense (RiAS) is the latest and has shown to exhibit effective antisense activity with exceptional stability, natural nucleotide composition and easy production. Successful antisense activity is also heavily dependent on the efficient cellular uptake of antisense molecules (Matsuda et al., 1996) . Antisense transfection mediated by cationic lipids can be further enhanced by employing a DNA þ Peptide þ Lipid (DPL) transfection complex composed of DNA (antisense)/Peptide (a protein transduction domain)/ Lipids (cationic lipids).
In the present study, a ribbon antisense molecule to hTR (hTR-RiAS) is designed and tested for the effective removal of hTR RNA in several cancer cell lines that show telomerase activation. To achieve an optimal antisense activity, an enhanced uptake of hTR-RiAS was adopted by employing the DPL complex for both in vitro and in vivo applications.
Results

Construction of hTR-RiAS oligonucleotides to hTR RNA
Finding an effective target site for an antisense is important in obtaining good antisense activity, which may be performed by the overlapping simulation of secondary structures of target RNA (Matsuda et al., 1996) . The entire sequence of hTR RNA was examined to find target sites that were readily accessible to antisense molecules. Five target sites were chosen, and the antisense (AS) sequences to the target sites were named hTR 13701 (36 bases), hTR 13702 (40 bases), hTR 13703 (40 bases), hTR 13704 (31 bases), and hTR 13705 (31 bases). Mismatch and scramble oligos were designated as hTR 13706 (36 bases) and hTR 13707 (36 bases), respectively. The mismatch oligos have eight mismatched bases in the hTR 13701 sequence (Figure 1a) .
AS molecules to the five potential target sites were designed to form ribbon AS-oligos (RiAS) that were shown to exhibit excellent stability to nucleases and enhanced antisense activity (Moon et al., 2000a, b) . RiAS has two identical antisense loops at both ends and a stem interconnecting the loops (Figure 1b) . Shown in the figure is one of the five hTR antisense sequences, marked by bold letters, in the loops. As expected, the RiAS molecules were shown to be retarded on a polyacrylamide gel. Whereas the RiAS molecules showed resistance to exonuclease I and observed as a major band (100 mer) on the gel, the linear precursor oligos were completely degraded by exonuclease I in an hour (data not shown).
The RiAS molecules were then examined for antisense activity in HeLa cells. Total RNA was purified 24 h after antisense transfection and used for RT-PCR. Among the five different RiAS molecules to hTR, the one derived from the hTR 13701 sequence was able to ablate hTR mRNA to completion (Figure 1c) . The ribbon AS-oligo was termed hTR-RiAS and adopted for further studies.
Specific reduction of hTR RNA by hTR-RiAS oligos
When examined for hTR expression, all five cancer cell lines studied were found to be positive for hTR expression. These were two lung cancer cell lines (A549 and NCI-H596), a colon cancer cell line (SW480), a cervix cancer cell line (HeLa), and a melanoma cell line (A375SM). We then set out to test the antisense activity of hTR-RiAS. Cellular uptake of hTR-RiAS oligos were enhanced by adopting the DPL transfection system, for which a detailed description is found in the Materials and methods section.
When hTR-RiAS was transfected into A549 cells, hTR RNA was found to be almost completely eliminated (Figure 2a ). Similar levels of antisense activity were also observed in four other cell lines of HeLa, SW480, NCI-H596, and A375SM, indicating a broad utility of hTR-RiAS in various cancer cells (Figure 2b-e) . When A549 and HeLa cells (each 1 Â 10 5 cells/well) were treated with hTR-RiAS, hTR RNA was reduced by 60% at 6.4 nM, 75% at 32 nM, and some 90% at 64 nM, showing dose-dependent antisense activity (Figure 2a,b) . In contrast, both scramble and mismatch oligos exhibited only mild or no reductions of hTR RNA. Treatment of cationic lipids alone failed to reduce the level of hTR RNA. Transfection of hTRRiAS did not affect b-actin expression as shown in the lower panels of each figure (Figure 2a-e) . Reduction of the target RNA by hTR-RiAS was then reconfirmed quantitatively with real-time RT-PCR. As compared to control treatments of naive, lipids alone, and mismatch oligos, cells treated with hTR-RiAS showed more than (Figure 2f ). In contrast, bactin expression was not affected in HeLa cells with control treatments. These results confirm the specific and potent antisense activity of hTR-RiAS following efficient uptake.
The mechanism of the antisense activity by hTRRiAS was then studied using an RNase H assay. When in vitro RNA transcript of an hTR fragment was treated with RNase H, the transcript was digested to completion, leaving only faint bands of the fragmented RNA. In contrast, the mismatch control failed to induce RNase H activity, showing no degradation of the RNA transcript ( Figure 2g ). The results support that hTRRiAS, with its natural nucleotide composition, effectively induces the RNase H-mediated cleavage of RNA in RNA-DNA duplex.
Telomerase activity was further studied in HeLa cells treated with hTR-RiAS. The cells treated with the hTRRiAS showed some 80% reduction of telomerase activity in comparison to those in the cells with control treatments of naive, lipids alone, and mismatch oligo (Figure 3a, b) .
Rapid inhibition of cancer cell growth by hTR-RiAS
Potency of antisense activity of hTR-RiAS was tested for the growth inhibition of HeLa and SW480 cells. When treated with hTR-RiAS, HeLa cell growth was inhibited in a time-dependent manner by 36, 53, and 70% in 1, 2, and 3 days, respectively. Similarly, the viability of SW480 cells was inhibited by 25, 55, and 76% in 1, 2, and 3 days, respectively ( Figure 4 ). In contrast, when hTR-RiAS was studied for the antisense activity in two normal fibroblast cells, MRC-5 and WI38, both cell lines were not significantly affected by hTR-RiAS in all durations of antisense treatments. Control treatments with cationic lipids alone and mismatch oligos also failed to show growth inhibition of significance. Comparable levels of growth inhibition by hTR-RiAS were observed in the four other cancer cell lines examined. Microscopic observations on cell morphology also correlated with growth inhibition as cancer cells treated with hTR-RiAS underwent morphological changes (data not shown).
Antisense to telomerase components including hTR RNA has been reported to cause apoptosis. We investigated whether the rapid inhibition of cancer cell growth was also due to apoptosis induced by hTRRiAS. To prove this, cell cycle analysis was performed on HeLa and SW480 cells. The cells treated with hTRRiAS for 72 h were subjected to flow cytometric analysis using the PI staining method. The cells transfected with hTR-RiAS showed increased percentages of cells at the sub-G 0 arrest, indicating apoptotic cell death of HeLa and SW480. In contrast, cell cycle arrest was not detected in cells with treatments of naive, lipids alone, and mismatch oligos (Figure 5a ,b). DNA fragmentation assays were then performed on HeLa and Hep3B cells to assess the degree of apoptosis. The cancer cell lines treated with hTR-RiAS showed a typical pattern of ladder formation, showing that apoptotic cell death was responsible for the rapid inhibition of cancer cell growth (Figure 5c,d ).
Effective antisense activity of hTR-RiAS in an animal tumor model
Having observed an effective ablation of hTR RNA and a subsequent reduction of telomerase activity in cancer cell lines, antisense activity of hTR-RiAS was then examined for its deterrence of tumor growth in animals. Tumors were formed in nude mice by the subcutaneous inoculation of SW480 that easily forms a tumor. Tumors formed were injected with hTR-RiAS intratumorally when tumor size reached 40-50 mm 3 . Whereas hTR-RiAS was able to halt tumor growth to The TRAP products were quantified by absorbance reading of reaction mixtures using ELISA completion, control treatments with naive and scramble oligos failed to block tumor growth, resulting in the increase of tumor mass by some 300% in 3 weeks (Figure 6a ). Tumor tissues in animals were then examined for hTR expression using quantitative realtime RT-PCR (qRT-PCR). Whereas tumors treated with hTR-RiAS showed almost total reduction of hTR RNA, tumors with naive and mismatch controls showed a normal level of hTR RNA (Figure 6b ,c). In contrast, the level of b-actin RNA was not affected in tumors with naive and mismatch treatments.
Apoptotic cell death was examined further for its role in the reduction of tumor growth using an in situ cell death detection kit. A vast majority of cells in the tumor tissue treated with hTR-RiAS were found to be positive for apoptosis, detected with the TUNEL assay. The extent of apoptosis was calculated in each group for the percent apoptotic cells to total cell numbers. The group treated with hTR-RiAS showed tumor cells with apoptosis at about 72%. By contrast, some 3 and 12% tumor cells were positive for apoptosis, respectively, with naive and mismatch treatments (Figure 7) . These results confirmed that the blockade of tumor growth in mice injected with hTR-RiAS was due to apoptosis.
Discussion
In the present study, we demonstrated the potent antitumor activity of hTR RiAS when combined with enhanced cellular delivery using the DPL system. Telomerase is a multicomponent enzyme complex, composed of the telomerase RNA hTR, catalytic subunit hTERT, and telomerase-associated protein TP1. Since hTR is an essential component of the human telomerase complex, targeting hTR to inhibit telomerase activity has been attempted with different approaches of gene silencing, such as antisense, ribozymes and more recently siRNA (Norton et al., 1996; Glukhov et al., 1998; Kondo et al., 1998; Kosciolek et al., 2003) . The (Avilion et al., 1996) .
Telomerase activity is detected in 85-90% of human tumors, but not in most somatic cells, indicating a broad involvement of hTR expression in human malignancy (Kim et al., 1994; Kondo et al., 2000) . All human cancer cell lines studied exhibited hTR expression and can be effectively targeted with hTR-RiAS. hTR-RiAS with enhanced cellular uptake often resulted in the total ablation of hTR RNA, effective inhibition of telomerase activity, and blockade of cancer cell proliferation.
We have reported superior properties of RiAS oligos that have a covalently closed structure with much enhanced stability as well as natural nucleotide composition. Conventional AS oligos with enhanced stability have adopted chemical modifications that have been blamed for various side effects. It has been reported that conventional antisense oligos require larger amount of antisense oligos ranging from 20 to 200 mg/ml to obtain biological effects that may not be entirely sequence specific. Various control and real-time RT-PCR data shown in this report demonstrate that hTR-RiAS was effective in lesser amounts. The inhibitory effect of hTRRiAS was sequence specific because mismatch and scramble RiAS oligos failed to exhibit any significant antisense effects. In addition, RiAS oligos was shown to have normal sequence specificity and induced RNase H activity. An additional merit of RiAS oligos is that it is unlikely to introduce undesired mutations in the genomic DNA during DNA replication or repair upon recycling of hydrolysed nucleotides from the antisense molecules.
In general, antisense oligos show poor cellular uptake due to anionic charges on the molecules polymeric backbone. Cellular uptake of antisense oligos can be enhanced by forming complexes with cationic lipids (Wheeler et al., 1996) . Although cationic lipids have several advantages such as low toxicity and simple production, their transfection efficiency needs large ). We have found that a simple DPL complex was able to enhance significantly the cellular uptake of ASoligos, often resulting in more than 90% cells positive for AS-oligo uptake. Thus, improved antisense activity shown in this report may be explained not only by the improved properties of AS-oligos, but also by the enhanced cellular uptake.
Antisense activity to hTR RNA was reported on telomere length and cell proliferation in cancer cells. When antisense RNA to hTR was expressed in HeLa cells, the cells showed significant shortening of telomere length after 1 month of treatment, followed by apoptotic cell death at 23-26 population doublings (Feng et al., 1995; Bisoffi et al., 1998) . They postulated that the cell death was due to shortened telomere length that caused chromosomal instability. An interesting observation was that 2-5A antisense oligos to hTR exhibited inhibition of telomerase activity and rapid reduction of cell viability in 4-6 days (Kondo et al., 1998; Mukai et al., 2000) . The rapid onset of growth inhibition was also demonstrated by ribozyme targeting the hTERT component (Kanazawa et al., 1996) . These studies suggest the existence of a 'fast track' pathway by which diminution of telomerase can interfere with growth of cancer cells and induce rapid cell death, presumably through apoptosis. The difference may be explained by different levels of inhibition of the telomerase complex. It should be noted that telomerase activity has been suggested to be associated with increased cellular resistance to apoptosis (Counter et al., 1998; Zhang et al., 1998; Holt et al., 1999; Fu et al., 2000; Zhu et al., 2000; Ren et al., 2001) .
Targeting telomerase in an effective manner would have potential utility in the treatment of various human cancers because telomerase is ubiquitously expressed in human tumors. hTR-RiAS often results in almost complete ablation of hTR RNA and blockade of tumor 
Materials and methods
Cell lines and cultures
The following human cancer cell lines were used: lung cancer cell lines (A549, NCI-H596), colon cancer cell line (SW480), cervix cancer cell line (HeLa), and melanoma cancer cell line (A375SM). Two normal fibroblast cells, MRC-5 and WI 38, were used as controls to test telomerase activity. HeLa and A375SM were purchased from ATCC (American Type Culture Collection, Rockville, MD, USA). MRC-5 was kindly supplied by Dr YC Sung of POSTECH (Pohang, Korea). WI38, A549, NCI-H596, and SW480 were obtained from the Korean Cell Bank (Seoul, Korea). A549 cells were cultured in DMEM, and HeLa, Hep3B, A375SM, MRC-5, and WI38 in EMEM. NCI H1299 was cultured in RPMI 1640, and SW480 cells in Leibovitz's L-15. Cell culture media were supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin/ streptomycin. Cell culture reagents including FBS were purchased from JBI (Daegu, Korea). Routine cell culture practices were strictly followed to keep proper cell density and features.
Synthesis of RiAS oligonucleotide
hTR-RiAS was synthesized using an Expedite 8909 DNA synthesizer (Applied Biosystem, Foster city, CA, USA). Antisense and control oligos (scramble and mismatch) were phosphorylated at the 5 0 end. Both antisense oligos to hTR and control oligos are to form stem-loop structures. The intramolecular stem is formed by complementary sequences at both 5 0 and 3 0 ends of each oligos. Two identical oligos molecules were joined by single-stranded sequences that were complementary to each other at their 5 0 ends. Oligo molecules were mixed and heated for 2 min at 951C and gradually cooled to room temperature. One unit of T4 DNA ligase was added and incubated for 24 h at 161C to generate a ribbon AS-oligos ligated covalently with dyad-symmetry. Ribbon AS-oligos consist of two loops and one stem connecting the two loops. The oligos were purified with the Poros HQ anion exchange column (PerSeptive Biosystems, Framingham, MA, USA). Anion exchange was performed by gradient elution with 1 M NaCl solutions. Purified oligos were dried by an evaporator, and desalted by reverse phase chromatography. Finally, desalted oligos were precipitated by ethanol and resuspended in ddH 2 O.
Preparation of the DPL system for enhanced transfection of hTR-RiAS
Cellular uptake of hTR-RiAS into cancer cells was enhanced by employing the DPL transfection system that was found to be effective in our laboratory. The peptide (49-57: Arg-Lys- Inhibition of telomerase activity by ribbon antisense to hTR AK Bajpai et al Lys-Arg-Arg-Gln-Arg-Arg-Arg) was derived from the protein transduction domain (PTD) of the HIV-1 Tat protein (Efthymiadis et al., 1998) . Antisense oligos (64 nM) were mixed with the peptide at a ratio of 1 : 3 (W/W) in 50 ml OPTI-MEM and incubated at room temperature for 15 min. Lipofectaminet (Invitrogen, Carlsbad, CA, USA) was volume-adjusted to 50 ml with OPTI-MEM and incubated at room temperature for 15 min. The lipofectamine solution was then mixed with the DNA/peptide solution drop by drop with gentle agitation. The DPL complex was incubated for 20 min at room temperature and was gently overlaid on cultured cells. Transfection was performed for 5 h at 371C. Transfectants were then added with 100 ml of 20% FBS in OPTI-MEM, and incubated until a desired time for further analysis. The component ratio of the DPL complex was utilized at the ratio of 1 : 3 : 5 (W/W/W).
Determination of hTR RNA Levels
Cellular levels of hTR RNA were determined by RT-PCR. RNA preparation was carried out with Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA). Purified RNA (1 mg) was subjected to RT-PCR in a 50 ml reaction volume using an Access RT-PCR kit (Promega, Madison, WI, USA) as recommended by the manufacturer. The Amplification of cDNA was carried out in a PTC-100t thermal cycler (MJ Research, Watertown, MA, USA), employing hTR-specific primers 5 0 -gtctaaccctaactgagaag-3 0 as a forward primer and 5 0 -ctagaatgagaagg-3 0 as a backward primer. PCR conditions were as follows: 35 cycles of 941C for 30 s, 581C for 1 min, 681C for 1 min, followed by one cycle of 721C for 7 min.
For quantification of hTR RNA, qRT-PCR was performed using a DNA Engine 2 OPTICONt thermal cycler (MJ Research Inc. Waltham, MA, USA). The hTR RNA level was measured by a continuous fluorescence detector using the DyNAmo HS SYBR Green qRT-PCR kit (MJ Research, Waltham, MA, USA) according to the manufacturer's instruction. To normalize the amount of total RNA present in each reaction, b-actin gene was amplified simultaneously. RT-PCR reactions were carried out for 10 min at 951C, and 44 cycles for 30 s at 941C, 1 min at 581C, 2 min at 681C. Melting curves from 65 to 951C were read every 0.21C, held for 1 s and finally 10 s at 251C. In the present study, the 2 ÀDDC T method [DDC T ¼ DC T (target gene)ÀDC T (b-actin)] were used to analyse the relative changes in gene expression (Livak and Schmittgen, 2001) .
RNase H-mediated cleavage assay
The RT-PCR fragment (246 bp) was amplified with 5 0 -cggga tccgtctaaccctaactgag-3 0 as a forward primer and 5 0 -cgga attctgggtgcctccggagaa-3 0 as a backward primer. The in vitro transcription was performed using the Riboprobe s (Promega, Madison, WI, USA) as per the manufacturer's recommendation. The RNA products were then recovered by NH 4 OAc/ ethanol precipitation and used in the cleavage reactions. The hTR transcript (20 mM, 342 bp) and hTR-RiAS (200 mM) were hybridized in 60 mM Tris-HCl (pH 7.5) containing 2 mM dithiothreitol, 60 mM KCl, and 2.5 mM MgCl 2 . The reaction was incubated at 681C for 10 min prior to the addition of 1 ml RNase H (6 U/ml, Takara Shuzo Co., Ltd), allowed to proceed for 1 h at 371C and stopped by the addition of 10 ml gel loading buffer (95% formamide, 0.025% w/v xylene cyanol, 0.025% w/v bromophenol blue and 1 Â TBE). The products were separated by electrophoresis in a 6% denaturing polyacrylamide gel.
Cell viability assay with XTT
Percent growth inhibition of different cell lines (HeLa, SW480, MRC-5 and WI38) was determined by XTT assays (JBI, Daegu, Korea). Cells were plated at a density of 5 Â 10 3 cells/ well (0.1 ml) in 96-well flat-bottomed microtiter plates and incubated overnight at 371C. The next day, cells were transfected with hTR-RiAS oligos in a 50 ml volume for 6 h. The first day of the treatment was designated as Day 0. The cell viability of treated cells was expressed as the percentage to the number of control cells.
Telomerase activity (TRAP) assay
Telomerase activity was determined by using a TRAeze ELISA Telomrease Detection Kit (Chemicon, Temecula, CA, USA), as recommended by the manufacturer. HeLa cells were seeded at 2.5 Â 10 5 cells/ml and incubated overnight at 371C. Cells were transfected with hTR-RiAS and incubated for 24 h. Cells were then pretreated with 200 ml Chaps lysis buffer (10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1mM EGTA, 5 mM b-mercaptoethanol, 0.5% Chaps, 10% glycerol, and 0.1 mM PMSF) and incubated in ice for 30 min. The lysates were centrifuged at 15 000 g for 30 min at 41C, and the supernatant was rapidly frozen and stored at À801C. The protein concentration was measured using a BCA Protein determination kit (Pierce, IL, USA). The assays were performed at 301C for 30 min for the telomere extension, followed by telomere amplification of 33 cycles using two-step PCR, 941C for 30 s, and 551C for 30 s. The amount of TRAP products was determined by the measurement of their absorbance value at A 450-690 . Negative control reactions were performed by the incubation of cell extracts with 1 mg/ml RNase A for 20 min at 371C. In addition, to confirm the ELISA results, amplified products were run on 10% nondenaturing polyacrylamide gel. Bands were then visualized by staining with SYBR Green I (Sigma) and images were captured using an AlphaImager 1220, a gel documentation apparatus (Alpha Innotech, San Leandro, CA, USA).
DNA fragmentation assay
Detection of apoptosis was performed with DNA fragmentation assays. In brief, 1 Â 10 6 cells were plated in each well of a six-well plate 1 day prior to hTR-RiAS treatment for 24 h. The cells were harvested, washed twice with PBS, and lysed with a lysis buffer containing 0.5% NP-40, 20 mM EDTA, and 10 mM Tris-HCl (pH 8.0). After centrifugation, the supernatant was treated with proteinase K (0.1 mg/ml) for 4 h at 501C, and followed by RNase A (0.2 mg/ml) treatment for 2 h at 371C. DNA was precipitated by adding 0.1 volume of 3 M ammonium acetate and 2.5 volume of ice-cold ethanol and stored for 12 h at À201C. DNA was dissolved in TE buffer (pH 8.0) and separated on 1.8% agarose gel.
Apoptotic cell cycle analysis
Cells were seeded on 12-well plate (2.5 Â 10 5 /well) and preincubated overnight in a humidified atmosphere of 5% CO 2 and 371C before hTR-RiAS treatment. Cells were washed once with PBS, followed by trypsinization and final resuspension in ice-cold PBS. Cell suspensions were fixed and permeabilized with ice-cold 70% ethanol. After treating the cells with 0.1 mg/ml RNase A (Sigma) at 371C for 10 min, DNA content was determined by staining with propidium iodide (PI, Sigma) at 0.01 mg/ml for 30 min. Cell cycle pattern was determined by flow cytometry using a FACScan flow-cytometry system (Becton Dickinson, Franklin Lakes, NJ, USA).
In vivo studies
For subcutaneous tumor formation, SW480 cells (1 Â 10 7 ) in 200 ml PBS were injected subcutaneously into the right flank of 6-8-week-old male BALBc (nu/nu) nude mice (six mice for each group). Animals were monitored regularly for tumor occurrence, size and weight. Tumor growth was monitored with a caliper every alternate day. After reaching an adequate tumor size (40-50 mm 3 ), animals were injected intratumorally with either OPTI-MEMI alone, hTR-RiAS (100 mg/mouse), or mismatched oligos (100 mg/mouse). The RiAS oligos were mixed with the Tat NLS peptide at the ratio of 1 : 2 and administered 3 times on alternate days.
For histological apoptotic TUNEL assay, mice were killed by cervical dislocation a day after the last treatment, and tumors were removed and fixed in 10% formalin. Tissue sections were cut to 4 mm thickness from specimen embedded with the Paraplast embedding medium (Oxford, St Louis, MO, USA). The specimen was stained for an apoptotic TUNEL assay using Apoptosis Detection system (Promega, Madison, WI, USA) according to the manufacture's instructions.
Statistical analysis
All data were made in triplicate, and results were expressed as means7standard deviation (s.d.). Statistical significance was determined by Student's t-test.
